- recruitingPHASE1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
This study is testing a new medicine, INCA33890, for people with advanced or spreading solid cancers. Doctors want to see how safe the medicine is, what side effects it causes, and find the best dose to give.
United States · China · Denmark - recruitingPHASE1
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
This study looks at a new treatment called MK-0472 for advanced or spreading cancers. It's given alone or with other medicines like pembrolizumab or MK-1084 to see how well it works and if it's safe.
United States · Canada · Chile - recruitingPHASE1, PHASE2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
This study is looking at a new drug called repotrectinib for advanced cancers that have specific gene changes (ALK, ROS1, or NTRK). It aims to find the best dose and see how well it works in shrinking tumours and how safe it is.
United States · Australia · Belgium - active not recruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
This study is testing a new medicine, RO7566802, by itself and with another drug, atezolizumab, for people with advanced solid tumours. It aims to check if the treatment is safe, how it works in the body, and if it helps shrink tumours. It's an early-stage study.
United States · Australia · Canada - ongoing, recruitingTherapeutic use (Phase IV)
Open-label Rollover Study to Evaluate Long-Term Safety in Subjects with Metastatic Solid Tumors that are Benefiting from Continuation of Therapy with Sacituzumab Govitecan
This study looks at the long-term safety of a treatment called Trodelvy for people with advanced cancers that have spread. It aims to see how safe the drug is when used over a longer period in patients who are already doing well on it.
Spain · Belgium · France - recruitingPHASE1, PHASE2
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
This study looks at a new drug, repotrectinib, for children and young adults (up to 25) with certain advanced cancers. It checks if the drug is safe and helps shrink tumours that have specific genetic changes called ALK, ROS1, or NTRK.
United States · Australia · Canada